Abstract
The current diagnostic threshold for diabetes mellitus is imposed on a continuous distribution of blood glucose measurement. A more clinical approach estimates a threshold above which the rate of diabetes-specific complications rises steeply. However, the diagnostic threshold for diabetes is essentially established on the risk of microvascular and not cardiovascular complications. Indeed, while there appears to be a continuous relationship between blood glucose, cardiovascular risk and overall mortality, this association extends into the sub-diabetic range, with no threshold identified. In this regard, the assumption that the diagnosis of diabetes can effectively identify patients at elevated risk of cardiovascular morbidity and mortality is potentially flawed, and questions the utility of diabetes status (as a dichotomous variable) for the assessment and management of cardiovascular risk. Indeed, the increased risk of cardiovascular complications may not be related to diabetes status per se but the frequent association of diabetes with a high-risk phenotype, now recognised as the so-called ‘metabolic syndrome’. By implication, cardiovascular disease prevention should not be dominated by a drive for the prevention of diabetes, but this broader clinical syndrome of increased cardiovascular risk.
Keywords: oral glucose tolerance testing, cardiovascular risk, dyslipidaemia, International Diabetes Federation, metabolic syndrome
Current Pharmaceutical Design
Title: From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Volume: 13 Issue: 25
Author(s): Hoong Sern Lim and Gregory Y.H. Lip
Affiliation:
Keywords: oral glucose tolerance testing, cardiovascular risk, dyslipidaemia, International Diabetes Federation, metabolic syndrome
Abstract: The current diagnostic threshold for diabetes mellitus is imposed on a continuous distribution of blood glucose measurement. A more clinical approach estimates a threshold above which the rate of diabetes-specific complications rises steeply. However, the diagnostic threshold for diabetes is essentially established on the risk of microvascular and not cardiovascular complications. Indeed, while there appears to be a continuous relationship between blood glucose, cardiovascular risk and overall mortality, this association extends into the sub-diabetic range, with no threshold identified. In this regard, the assumption that the diagnosis of diabetes can effectively identify patients at elevated risk of cardiovascular morbidity and mortality is potentially flawed, and questions the utility of diabetes status (as a dichotomous variable) for the assessment and management of cardiovascular risk. Indeed, the increased risk of cardiovascular complications may not be related to diabetes status per se but the frequent association of diabetes with a high-risk phenotype, now recognised as the so-called ‘metabolic syndrome’. By implication, cardiovascular disease prevention should not be dominated by a drive for the prevention of diabetes, but this broader clinical syndrome of increased cardiovascular risk.
Export Options
About this article
Cite this article as:
Lim Sern Hoong and Lip Y.H. Gregory, From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept, Current Pharmaceutical Design 2007; 13 (25) . https://dx.doi.org/10.2174/138161207781663028
DOI https://dx.doi.org/10.2174/138161207781663028 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Response to <i>Letter to the Editor</i> by Briana and Malamitsi-Puchner: Effects of Pregnancy-induced Insulin Resistance on the Fetus and the Future Development of Metabolic Diseases in Adulthood
Current Vascular Pharmacology Microbial Agents, Immune Function and Atheromatosis: The Chlamydophila pneumoniae Role
Current Immunology Reviews (Discontinued) A Proposal for a New Classification of Type 1 Diabetes Mellitus Based on Clinical and Immunological Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Review Metabolomics: A New Approach to Drug Delivery in Perinatology
Current Medicinal Chemistry Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis
Vascular Disease Prevention (Discontinued) The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
Current Vascular Pharmacology Role of Hyperphosphatemia on Cardiovascular Disease in Dialysis Patients
Vascular Disease Prevention (Discontinued) Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology Myocardial Revascularization for the Elderly: Current Options, Role of Off-pump Coronary Artery Bypass Grafting and Outcomes
Current Cardiology Reviews A Sweeping Role for MicroRNAs in Neuronal Disease, Vascular Disorders, and as Prognostic Indicators
Current Neurovascular Research Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Incidence of Type 2 Diabetes Among Patients Exposed to the Combination of Pravastatin and Paroxetine
Current Drug Safety A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Current Vascular Pharmacology Early Prediction of Preeclampsia: Hope for Early Intervention?
Current Women`s Health Reviews Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators
Current Vascular Pharmacology Recent Developments of C-Aryl Glucoside SGLT2 Inhibitors
Current Medicinal Chemistry Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology Editorial:Nutrition Transition in Developing Countries: Focus on South Asia
Current Diabetes Reviews